Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio recording of Earnings Call for the quarter ended June 30, 202220-07-2022
20-07-2022
Q1FY23 Quarterly Result Announced for Gland Pharma Ltd.
Gland Pharma Announced Q1FY23 Result : Gland Pharma’s Q1FY23 Revenue stood at Rs 8,569 Mn with PAT margin of 25% Continued supply disruption, cost escalation and the Company’s decision to shut down two of its manufacturing lines for productivity improvement have affected the business for the quarter. Revenue from operations during the quarter has declined by 26% as compared to corresponding quarter of the previous year, which was higher due to COVID related product sales. The Company maintained a healthy EBITDA margin of 37% and PAT margin of 25% during the quarter. The Company has generated Rs 3,328 Mn of cash flow from operations during Q1FY23. As of June 2022, the company had total Rs 37,853 million of Cash. Commenting on the results, Mr. Srinivas Sadu, MD & CEO of Gland Pharma said “While market demand for our products remained strong, continuing supply disruptions in the midst of challenging macro environment has impacted our growth for the first quarter of fiscal 2023. The revenue for the quarter stood at Rs 8,569 Mn and our PAT stood at Rs 2,292 Mn. We ensured timely new product launches which is key to our sustainable business growth. In spite of pricing pressure in the US market and inflationary costs, we managed to improve our margin. We are continuously investing into our people, infrastructure and portfolio to expand our global footprint.” Result PDF20-07-2022
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation on Q1FY23 Financial Results20-07-2022
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on Q1FY23 (Quarter ended June 30, 2022) Financial Results20-07-2022
Gland Pharma Ltd - 543245 - Unaudited Financial Results For The Quarter Ended June 30, 2022
The Board of Directors at its meeting held on July 20, 2022 has inter-alia approved the Unaudited financial results of the Company for the quarter ended June 30, 2022.20-07-2022
Gland Pharma Ltd - 543245 - Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended June 30, 2022
The Board of Directors at its meeting held on July 20, 2022 has inter-alia approved the Unaudited financial results of the Company for the quarter ended June 30, 2022.20-07-2022
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earnings Conference Call - Q1FY2305-07-2022
Gland Pharma Ltd - 543245 - Board Meeting Intimation for Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2022
Gland Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/07/2022 ,inter alia, to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 202204-07-2022
Buy Gland Pharma; target of Rs 3700: Motilal Oswal
Motilal Oswal is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 3700 in its research report dated June 25, 2022.27-06-2022